达格列净FDA标签在美射血分数降低心衰患者中的适用性:GWTG-HF注册研究
结果显示81.1%患者符合标签标准,各站点中位比例81.1%,无2型糖尿病者比例更高(85.5% vs 75.6%)。最常见不符合原因为出院时eGFR<30 mL/min/1.73 m2(18.5%)。
要点
- 约4/5的HFrEF住院患者符合达格列净FDA标签,支持广泛适用性。
- 无2型糖尿病者符合比例高于有2型糖尿病者(85.5% vs 75.6%)。
- 不符合标签最常见原因为出院时eGFR<30 mL/min/1.73 m2(18.5%)。
核心结论
- 在当代美国心衰住院注册中,约4/5的HFrEF患者(伴或不伴2型糖尿病)符合达格列净起始标准,支持其广泛推广至美国临床实践。
研究设计与样本
- 将FDA标签(排除eGFR<30 mL/min/1.73 m2、透析及1型糖尿病)应用于注册样本,分析时间为2020年4月1日至6月30日。
主要发现
- 在355个有10例及以上住院患者的站点中,各站点符合标签的中位比例为81.1%(IQR 77.8%-84.6%)。
- 符合比例在各研究年份相似(IQR 80.4%-81.7%),无2型糖尿病者高于有2型糖尿病者(85.5% vs 75.6%)。
- 不符合FDA标签最常见原因为出院时eGFR<30 mL/min/1.73 m2(18.5%)。
关键数值与推荐
- FDA标签排除标准:eGFR<30 mL/min/1.73 m2、透析、1型糖尿病。
- 各站点符合比例中位数81.1%(IQR 77.8%-84.6%)。
- 无2型糖尿病者符合比例85.5%,有2型糖尿病者75.6%。
- 出院时eGFR<30 mL/min/1.73 m2者占18.5%。
临床怎么用
- 多数HFrEF住院患者符合达格列净起始标准,可考虑在出院前启动。
- 应评估eGFR,约1/5患者因出院时eGFR<30 mL/min/1.73 m2不符合标签。
- 无2型糖尿病者同样多数符合,不应仅因无糖尿病而忽略用药。
局限性
- 注册数据可能未完全反映真实世界用药障碍,如费用和耐受性。
- 与DAPA-HF试验相比,GWTG-HF中循证心衰治疗使用率较低。
- 研究仅基于FDA标签标准,未评估实际起始治疗率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In May 2020, dapagliflozin was approved by the US Food and Drug Administration (FDA) as the first sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction (HFrEF), based on the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. Limited data are available characterizing the generalizability of dapagliflozin to US clinical practice. OBJECTIVE: To evaluate candidacy for initiation of dapagliflozin based on the FDA label among contemporary patients with HFrEF in the US. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included 154 714 patients with HFrEF (left ventricular ejection fraction ≤40%) hospitalized at 406 sites in the Get With the Guidelines-Heart Failure (GWTG-HF) registry admitted between January 1, 2014, and September 30, 2019. Patients who left against medical advice, transferred to an acute care facility or to hospice, or had missing data were excluded. The FDA label (which excluded patients with an estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2, those undergoing dialysis, and those with type 1 diabetes) was applied to the GWTG-HF registry sample. Data analyses were conducted from April 1 to June 30, 2020. MAIN OUTCOMES AND MEASURES: The proportion of patients hospitalized with HFrEF who would be candidates for dapagliflozin under the FDA label. RESULTS: Among 154 714 patients hospitalized with HFrEF, 125 497 (81.1%; 83 481 men [66.5%]; mean [SD] age, 68 [15] years) would be candidates for dapagliflozin according to the FDA label. Across 355 sites with patients with 10 or more hospitalizations, the median proportion of candidates for dapagliflozin according to the FDA label was 81.1% (interquartile range, 77.8%-84.6%) at each site. This proportion was similar across all study years (interquartile range, 80.4%-81.7%) and was higher among those without type 2 diabetes than with type 2 diabetes (85.5% vs 75.6%). Among GWTG-HF participants, the most frequent reason for not meeting the FDA label criteria was eGFR less than 30 mL/min/1.73 m2 at discharge (18.5%). Among 75 654 patients with available paired admission and discharge data, 14.2% had an eGFR less than 30 mL/min/1.73 m2 at both time points, while 3.8% developed an eGFR less than 30 mL/min/1.73 m2 by discharge. Although there were more older adults, women, and Black patients in the GWTG-HF registry than in the DAPA-HF trial, most clinical characteristics were qualitatively similar between the 2 groups. Compared with the DAPA-HF trial cohort, there was lower use of evidence-based HF therapies among patients in GWTG-HF. CONCLUSIONS AND RELEVANCE: These data from a large, contemporary US registry of patients hospitalized with heart failure suggest that 4 of 5 patients with HFrEF (with or without type 2 diabetes) would be candidates for initiation of dapagliflozin, supporting its broad generalizability to US clinical practice.
引用
- Vaduganathan M, Greene SJ, Zhang S, et al. Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. JAMA Cardiol. 2021. PMID: 33185662. doi:10.1001/jamacardio.2020.5864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。